Crinetics Pharmaceuticals (CRNX) Non-Current Assets (2017 - 2026)

Crinetics Pharmaceuticals' Non-Current Assets history runs 10 years deep, the most recent figure standing at $78.9 million for Q1 2026.

• On a quarterly basis, Non-Current Assets rose 12.29% year-over-year to $78.9 million in Q1 2026; TTM through Mar 2026 was $303.9 million, a 21.55% increase from a year earlier, with the FY2025 full-year figure at $77.9 million, up 31.6% from the prior year.
• Non-Current Assets grew to $78.9 million in Q1 2026 per CRNX's latest filing, from $77.9 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $78.9 million in Q1 2026 and bottomed at $5.0 million in Q1 2022.
• The 5-year median for Non-Current Assets is $60.8 million (2024), against an average of $46.1 million.
• Across the five-year window, Non-Current Assets declined 12.34% in 2022 and surged 903.16% in 2023, its largest moves.
• Year by year, Non-Current Assets stood at $7.0 million in 2022, then surged by 775.29% to $61.2 million in 2023, then slipped by 3.26% to $59.2 million in 2024, then soared by 31.6% to $77.9 million in 2025, then rose by 1.28% to $78.9 million in 2026.
• Per Business Quant, the three latest CRNX Non-Current Assets figures stand at $78.9 million (Q1 2026), $77.9 million (Q4 2025), and $74.8 million (Q3 2025).